enfortumab vedotin
Selected indexed studies
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. (N Engl J Med, 2024) [PMID:38446675]
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. (N Engl J Med, 2021) [PMID:33577729]
- Enfortumab Vedotin. (, 2006) [PMID:33630480]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. (2024) pubmed
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. (2021) pubmed
- Enfortumab Vedotin. (2006) pubmed
- Enfortumab Vedotin. (2012) pubmed
- Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer. (2024) pubmed
- Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. (2023) pubmed
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. (2026) pubmed
- Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial. (2025) pubmed
- Enfortumab vedotin to treat urothelial carcinoma. (2020) pubmed
- Enfortumab Vedotin in urothelial cancer. (2020) pubmed